MX2021003094A - Composiciones que comprenden un inhibidor de crac y un corticosteroide y métodos de uso de estas. - Google Patents

Composiciones que comprenden un inhibidor de crac y un corticosteroide y métodos de uso de estas.

Info

Publication number
MX2021003094A
MX2021003094A MX2021003094A MX2021003094A MX2021003094A MX 2021003094 A MX2021003094 A MX 2021003094A MX 2021003094 A MX2021003094 A MX 2021003094A MX 2021003094 A MX2021003094 A MX 2021003094A MX 2021003094 A MX2021003094 A MX 2021003094A
Authority
MX
Mexico
Prior art keywords
corticosteroid
compositions
methods
crac
crac inhibitor
Prior art date
Application number
MX2021003094A
Other languages
English (en)
Inventor
Srikant Viswanadha
Swaroop Kumar Venkata Satya Vakkalanka
Original Assignee
Rhizen Pharmaceuticals A G
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhizen Pharmaceuticals A G filed Critical Rhizen Pharmaceuticals A G
Publication of MX2021003094A publication Critical patent/MX2021003094A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La presente divulgación se refiere a un método para tratar una enfermedad o afección autoinmunitaria, respiratoria y/o inflamatoria (tal como psoriasis, artritis reumatoide, asma o EPOC) mediante la administración de al menos un modulador de calcio activado por liberación de calcio (CRAC) (tal como un inhibidor de CRAC) y al menos un corticosteroide.
MX2021003094A 2018-09-14 2019-09-13 Composiciones que comprenden un inhibidor de crac y un corticosteroide y métodos de uso de estas. MX2021003094A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201841034710 2018-09-14
PCT/IB2019/057746 WO2020053834A1 (en) 2018-09-14 2019-09-13 Compositions comprising a crac inhibitor and a corticosteroid and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2021003094A true MX2021003094A (es) 2021-05-12

Family

ID=68242781

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021003094A MX2021003094A (es) 2018-09-14 2019-09-13 Composiciones que comprenden un inhibidor de crac y un corticosteroide y métodos de uso de estas.

Country Status (15)

Country Link
US (1) US20220040162A1 (es)
EP (1) EP3849552A1 (es)
JP (1) JP2022508468A (es)
KR (1) KR20210062023A (es)
CN (1) CN113557020A (es)
AU (1) AU2019340601A1 (es)
BR (1) BR112021004893A2 (es)
CA (1) CA3112907A1 (es)
CL (1) CL2021000616A1 (es)
CO (1) CO2021004013A2 (es)
EA (1) EA202190556A1 (es)
IL (1) IL281342A (es)
MX (1) MX2021003094A (es)
SG (1) SG11202102491RA (es)
WO (1) WO2020053834A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102587919B1 (ko) * 2022-07-22 2023-10-11 주식회사 넥스트젠바이오사이언스 신규한 헤테로사이클릭 화합물 및 이를 포함하는 오토탁신 저해용 약학 조성물

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU751139B2 (en) 1997-10-13 2002-08-08 Astellas Pharma Inc. Amide derivative
EP1143013A1 (en) 2000-04-03 2001-10-10 Warner-Lambert Company Methods and compositions for screening Icrac modulators
US7452675B2 (en) 2002-01-25 2008-11-18 The Queen's Medical Center Methods of screening for TRPM4b modulators
US7645588B2 (en) 2003-03-04 2010-01-12 Calcimedica, Inc. Composition comprising a cell comprising a STIM1 protein and an agent that modulates intracellular calcium and methods of use
CA2533594C (en) 2003-07-23 2013-04-02 Synta Pharmaceuticals, Corp. Compounds for inflammation and immune-related uses
TW200621232A (en) 2004-09-21 2006-07-01 Synta Pharmaceuticals Corp Compounds for inflammation and immune-related uses
WO2006050214A2 (en) 2004-10-29 2006-05-11 Chemicon International, Inc. Method and system for providing online authentication using biometric data
KR20070107022A (ko) 2005-01-07 2007-11-06 신타 파마슈티칼스 코프. 염증 및 면역 관련 용도를 위한 화합물
CA2595855C (en) 2005-01-25 2017-07-04 Synta Pharmaceuticals Corp. Pyrazine compounds for inflammation and immune-related uses
JP5221147B2 (ja) 2005-01-25 2013-06-26 シンタ ファーマシューティカルズ コーポレーション 炎症及び免疫に関連する用途に用いる化合物
EP2368912B1 (en) 2006-01-05 2017-05-03 Children's Medical Center Corporation Regulators of NFAT
WO2007087429A2 (en) 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Phenyl and pyridyl compounds for inflammation and immune-related uses
WO2007087427A2 (en) 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Thiazole and thiadiazole compounds for inflammation and immune-related uses
JP2009528273A (ja) 2006-01-25 2009-08-06 シンタ ファーマシューティカルズ コーポレーション 炎症および免疫関連使用用の置換ビアリール化合物
US7816535B2 (en) 2006-01-25 2010-10-19 Synta Pharmaceuticals Corp. Vinyl-phenyl derivatives for inflammation and immune-related uses
EP1983971A4 (en) 2006-01-25 2010-11-24 Synta Pharmaceuticals Corp SUBSTITUTED AROMATIC COMPOUNDS FOR USE AGAINST INFLAMMATION AND IMMUNE DISORDERS
ES2403368T3 (es) 2006-01-31 2013-05-17 Synta Pharmaceuticals Corporation Compuestos de piridilfenilo para la inflamación y usos inmunorrelacionados
TW200812587A (en) 2006-03-20 2008-03-16 Synta Pharmaceuticals Corp Benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses
JP2009530409A (ja) 2006-03-23 2009-08-27 シンタ ファーマシューティカルズ コーポレーション 炎症及び免疫関連使用用のベンゾイミダゾリル−ピリジン化合物
AU2007238225A1 (en) 2006-04-10 2007-10-25 Beth Israel Deaconess Medical Center CRAC modulators and use of same for drug discovery
US20080039392A1 (en) 2006-05-26 2008-02-14 The Regents Of The University Of California CRAC channel and modulator screening methods
US8779154B2 (en) 2006-09-26 2014-07-15 Qinglin Che Fused ring compounds for inflammation and immune-related uses
JP5538894B2 (ja) 2006-11-13 2014-07-02 シンタ ファーマシューティカルズ コーポレーション 炎症及び免疫関連使用のためのシクロヘキセニル−アリール化合物
WO2008103310A1 (en) 2007-02-16 2008-08-28 Synta Pharmaceuticals Corp. Substituted fused-ring compounds for inflammation and immune-related uses
NZ580195A (en) 2007-03-05 2012-03-30 Univ Queensland Targeting crac for breast cancer therapy and/or diagnosis
KR101217754B1 (ko) 2007-03-23 2013-01-02 더 퀸스 메디컬 센터 Ｓｔｉｍ2 활성을 측정하기 위한 분석 및 방법
EP2157979B1 (en) 2007-05-24 2018-07-11 Calcimedica, Inc. Calcium channel proteins and uses thereof
CA2695156A1 (en) 2007-08-01 2009-02-05 Synta Pharmaceuticals Corp. Vinyl-aryl derivatives for inflammation and immune-related uses
US8435996B2 (en) 2007-08-01 2013-05-07 Synta Pharmaceuticals Corp. Heterocycle-aryl compounds for inflammation and immune-related uses
JP5431323B2 (ja) 2007-08-01 2014-03-05 シンタ ファーマシューティカルズ コーポレーション 炎症および免疫関連用途のためのピリジン化合物
AU2008299220B2 (en) 2007-09-10 2011-07-21 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2009038775A1 (en) 2007-09-20 2009-03-26 Synta Pharmaceuticals Corp. Substituted benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses
US8389567B2 (en) 2007-12-12 2013-03-05 Calcimedica, Inc. Compounds that modulate intracellular calcium
AU2009204147A1 (en) 2008-01-07 2009-07-16 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
MX2011002149A (es) 2008-08-27 2011-04-05 Calcimedica Inc Compuestos que modulan el calcio intracelular.
US8524763B2 (en) 2008-09-22 2013-09-03 Calcimedica, Inc. Inhibitors of store operated calcium release
US20110257177A1 (en) 2008-09-22 2011-10-20 Calcimedica, Inc. Benzylthiotetrazole inhibitors of store operated calcium release
WO2010034011A2 (en) 2008-09-22 2010-03-25 Calcimedica, Inc. Phenylthiophenyldihydrobenzothiazepine inhibitors of store operated calcium release
CA2739303A1 (en) 2008-10-01 2010-04-08 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
US20110118281A9 (en) 2008-10-01 2011-05-19 Gary Bohnert Compounds for inflammation and immune-related uses
EP2350064A1 (en) 2008-10-01 2011-08-03 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
US8143269B2 (en) 2008-10-03 2012-03-27 Calcimedica, Inc. Inhibitors of store operated calcium release
WO2010048559A2 (en) 2008-10-24 2010-04-29 Calcimedica Inc. Phenylpyrazole inhibitors of store operated calcium release
EP2421834A1 (en) 2009-04-24 2012-02-29 Glaxo Group Limited Pyrazole and triazole carboxamides as crac channel inhibitors
WO2010122089A1 (en) 2009-04-24 2010-10-28 Glaxo Group Limited N-pyrazolyl carboxamides as crac channel inhibitors
EP2477982A4 (en) 2009-09-16 2013-04-03 Calcimedica Inc COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM
CN102574788A (zh) 2009-09-24 2012-07-11 弗·哈夫曼-拉罗切有限公司 作为crac调节剂的吲哚衍生物
US8993612B2 (en) 2009-10-08 2015-03-31 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
US8377970B2 (en) 2009-10-08 2013-02-19 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel
US20130079348A1 (en) 2010-03-03 2013-03-28 Calcimedica, Inc. Compounds that modulate intracellular calcium
DK2563776T3 (en) 2010-04-27 2016-09-19 Calcimedica Inc Relations that modulate intracellular calcium
JP2013525448A (ja) 2010-04-27 2013-06-20 カルシメディカ，インク． 細胞内カルシウムを調節する化合物
CN103180316A (zh) 2010-08-27 2013-06-26 钙医学公司 调节细胞内钙的化合物
US20120071516A1 (en) 2010-09-22 2012-03-22 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2012056478A1 (en) 2010-10-30 2012-05-03 Lupin Limited Oxazole and isoxazole crac modulators
WO2012079020A2 (en) 2010-12-09 2012-06-14 The Board Of Trustees Of The Leland Stanford Junior University Compounds that modulate store operated calcium channels
WO2012170931A2 (en) 2011-06-10 2012-12-13 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2012170951A2 (en) 2011-06-10 2012-12-13 Calcimedica, Inc. Compounds that modulate intracellular calcium
US20130090334A1 (en) 2011-10-05 2013-04-11 Hoffmann-La Roche Inc Azabenzoxazine derivatives as crac modulators
WO2013050270A1 (en) 2011-10-05 2013-04-11 F. Hoffmann-La Roche Ag Benzoxazine derivatives as crac modulators
WO2013059666A1 (en) 2011-10-19 2013-04-25 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2013059677A1 (en) 2011-10-19 2013-04-25 Calcimedica, Inc. Compounds that modulate intracellular calcium
US20130109720A1 (en) 2011-11-01 2013-05-02 Hoffmann-La Roche Inc. Indole inhibitors of crac
US20130158049A1 (en) 2011-12-20 2013-06-20 Hoffmann-La Roche Inc. 7-azaindole inhibitors of crac
US20130158040A1 (en) 2011-12-20 2013-06-20 Hoffmann-La Roche Inc. Diazaindole inhibitors of crac
US20130158066A1 (en) 2011-12-20 2013-06-20 Hoffmann-La Roche Inc. 4-azaindole inhibitors of crac
EP2844655A1 (en) 2012-05-02 2015-03-11 Lupin Limited Substituted pyridine compounds as crac modulators
IN2014MN02127A (es) 2012-05-02 2015-09-11 Lupin Ltd
WO2014043715A1 (en) 2012-09-17 2014-03-20 Calcimedica, Inc. Compounds that modulate intracellular calcium
US9512116B2 (en) 2012-10-12 2016-12-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
JP2016508152A (ja) 2013-01-10 2016-03-17 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Ｃｒａｃチャネル阻害薬としての、ピラゾリルをベースとするカルボキサミド類ｉ
CN104884058A (zh) 2013-01-10 2015-09-02 格吕伦塔尔有限公司 作为crac通道抑制剂的基于吡唑基的甲酰胺ii
CA2914132A1 (en) 2013-06-21 2014-12-24 Lupin Limited Substituted heterocyclic compounds as crac modulators
EP3013810A1 (en) 2013-06-24 2016-05-04 Lupin Limited Chromane and chromene derivatives and their use as crac modulators
EP2848615A1 (en) * 2013-07-03 2015-03-18 Almirall, S.A. New pyrazole derivatives as CRAC channel modulators
AR097325A1 (es) 2013-08-13 2016-03-09 Gruenenthal Gmbh Pirroles anillados
US9611263B2 (en) 2013-10-08 2017-04-04 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2015090580A1 (en) 2013-12-18 2015-06-25 Grünenthal GmbH Pyrazolyl-based carboxamides useful as calcium release activated calcium channel (icrac) inhibitors
WO2015197188A1 (en) 2014-06-24 2015-12-30 Grünenthal GmbH Pyrazolyl-based carboxamides as crac inhibitors
JP6764866B2 (ja) 2015-01-13 2020-10-07 ビブレオン バイオサイエンシーズ，エルエルシー Ｃａ２＋放出活性化Ｃａ２＋（ＣＲＡＣ）チャネルのモジュレーターおよびその薬学的使用
ITUA20164199A1 (it) 2016-06-08 2017-12-08 Univ Degli Studi Del Piemonte Orientale Amedeo Avogadro Modulatori di soce compisizioni e relativi usi
MX2019008875A (es) 2017-01-26 2019-10-24 Calcimedica Inc Composiciones de inhibidor del canal crac.
WO2019082124A1 (en) * 2017-10-26 2019-05-02 Rhizen Pharmaceuticals Sa COMPOSITION AND METHOD FOR THE TREATMENT OF LARGE B-CELL DIFFUSED LYMPHOMA

Also Published As

Publication number Publication date
JP2022508468A (ja) 2022-01-19
CA3112907A1 (en) 2020-03-19
CL2021000616A1 (es) 2021-10-15
IL281342A (en) 2021-04-29
SG11202102491RA (en) 2021-04-29
CN113557020A (zh) 2021-10-26
WO2020053834A1 (en) 2020-03-19
BR112021004893A2 (pt) 2021-06-01
EA202190556A1 (ru) 2021-08-24
AU2019340601A1 (en) 2021-05-13
CO2021004013A2 (es) 2021-07-19
EP3849552A1 (en) 2021-07-21
US20220040162A1 (en) 2022-02-10
KR20210062023A (ko) 2021-05-28

Similar Documents

Publication Publication Date Title
PH12019501812A1 (en) Compositions and methods for the treatment of hemoglobinopathies
PH12017501925A1 (en) Pyrazole compounds and method for making and using the compounds
MX2019014514A (es) Compuestos para tratar la enfermedad de huntington.
MY192848A (en) Compositions and methods for the treatment of hemoglobinopathies
PH12017500927A1 (en) Envenomation therapies and related pharmaceutical compositions, systems and kits
MY195443A (en) Tissue Factor Pathway Inhibitor Antibodies and uses Thereof
MX2022006575A (es) Uso de anticuerpos anti-il-23a para tratar enfermedades inflamatorias.
MX2017015132A (es) Hidrogel que porta inhibidor de hidrato.
PH12017502120B1 (en) A method and an apparatus for forming a lignin fraction, a lignin composition and its use
BR112019007400A2 (pt) composição de isocianato, e, método para a produção de um polímero de isocianato
BR112017014420A2 (pt) ?processo para desfosforação de metal fundido durante um processo de refino?
MX2021001471A (es) Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4).
MX2020006434A (es) Nuevos compuestos inhibidores del blanco mecanistico de rapamicina (mtor).
MX2021004454A (es) Anticuerpos anti-sinucleina.
MX2021003094A (es) Composiciones que comprenden un inhibidor de crac y un corticosteroide y métodos de uso de estas.
MX2021004387A (es) Composiciones y metodos para el tratamiento de sindrome vascular de ehlers danlos y trastornos asociados.
MX2017002088A (es) Uso de intensificador de hexametilentetramina para un sistema de acido emulsionado a temperatura alta.
GB2558439A (en) Settable compositions with variable set times
MX2021003888A (es) Nuevos compuestos utiles para el tratamiento de enfermedades cardiovasculares.
EA201790379A1 (ru) Способ лечения и композиции, содержащие двойной ингибитор киназ pi3k дельта-гамма и кортикостероид
BR112021017653A2 (pt) Composição de polímero superabsorvente
MX2022003834A (es) Materiales polimericos de ca?amo y metodos de fabricacion de los mismos.
MX2020009813A (es) Composiciones y metodos para tratar el prurito.
CR20200183A (es) Compuestos inhibidores de tirosina cinasa de bruton (btk)
PH12019500445A1 (en) Wear-resistant rubber compositions, systems, and methods